Vijaya Diagnostic Centre Limited has reported a significant financial performance for the fourth quarter of the fiscal year 2026, ending 31st March. The company, a leading integrated diagnostic chain in India, recorded a 26.6% year-on-year increase in revenue from operations, amounting to ₹2,193.8 million compared to ₹1,732.4 million in the same quarter of the previous year.
The company’s earnings before interest, taxes, depreciation, and amortisation (EBITDA) rose by 38.7% to ₹955.2 million from ₹688.6 million, with an EBITDA margin improvement of 379 basis points to 43.5%. Profit after tax (PAT) also saw a substantial rise of 37.5%, reaching ₹479.3 million, with the PAT margin increasing by 172 basis points to 21.8%.
For the full fiscal year 2026, Vijaya Diagnostic Centre achieved a revenue growth of 19.5% year-on-year, totalling ₹8,142.0 million. The EBITDA for the year increased by 23.3% to ₹3,369.4 million, while the PAT for FY26 stood at ₹1,729.8 million, reflecting a 20.3% increase from the previous year.
Operationally, the company conducted 4.49 million tests in Q4 FY26, an 18.5% increase from the previous year, with total footfall rising by 15.8% to 1.21 million. The average realisation per test and per footfall also improved by 6.8% and 9.3%, respectively.
Ms. Suprita Reddy, Managing Director and CEO, highlighted that FY26 was a landmark year for the company, with revenues surpassing ₹800 crore, translating into a 16.5% compound annual growth rate (CAGR) since listing. The company reported its highest-ever quarterly revenue in Q4 FY26, driven by strong growth in pathology and radiology segments.
Looking ahead, Vijaya Diagnostic Centre plans to expand its network by adding 4–5 hubs and 10–12 spokes in FY27. The company is also setting up a fully automated laboratory in Hyderabad and plans to introduce advanced genomic testing capabilities.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).